Allopurinol for chronic stable angina: old drug, new tricks?

The Lancet

Volumn 375, Issue 9732, 2010, Pages 2126-2127

  Antony, Renjith ^a   Dargie, Henry J ^a,b  

^a GOLDEN JUBILEE NATIONAL HOSPITAL   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTIANGINA PECTORIS AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IVABRADINE; NICORANDIL; NITRATE; RANOLAZINE; TRIMETAZIDINE; XANTHINE OXIDASE;

ANGIOCARDIOGRAPHY; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; ENERGY RESOURCE; ENZYME INHIBITION; GLUCOSE OXIDATION; HEART FAILURE; HEART HEMODYNAMICS; HUMAN; HYPERURICEMIA; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; OXIDATIVE STRESS; OXYGEN SUPPLY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVASCULARIZATION; RISK FACTOR; ST SEGMENT DEPRESSION; STABLE ANGINA PECTORIS;

EID: 77953613668     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60578-8     Document Type: Note

References (13)

1. Hemingway H., McCallum A., Shipley M., Manderbacka K., Martikainen P., and Keskimäki I. Incidence and prognostic implications of stable angina pectoris among women and men. JAMA 295 (2006) 404-411
2. In: Rose G.A., Blackburn H., Gillum R.F., and Prineas R.J. (Eds). Cardiovascular survey methods. 2nd edn. (1982), World Health Organization, Geneva
3. Hemingway H., Langenberg C., Damant J., Frost C., Pyörälä K., and Barrett-Connor E. Prevalence of angina in women versus men: a systematic review and meta-analysis of international variations across 31 countries. Circulation 117 (2008) 1526-1536
4. Timmis A.D., Feder G., and Hemingway H. Prognosis of stable angina pectoris: why we need larger population studies with higher endpoint resolution. Heart 93 (2007) 786-791
5. Weintraub W., Spertus J., Kolm P., et al., for the the COURAGE Trial Research Group. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med 359 (2008) 677-687
6. Noman A., Ang D.S.C., Ogston S., Lang C.C., and Struthers A.D. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet (2010) 10.1016/S0140-6736(10)60391-1 published online June 8.
7. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 359 (2002) 1269-1275
8. Khatib S., Farah H., and El-Migdadi F. Allopurinol enhances adenine nucleotide levels and improves myocardial function in isolated hypoxic rat heart. Biochemistry (Mosc) 66 (2001) 328-333
9. Anker S.D., Doehner W., Rauchaus M., et al. Uric acid and survival in chronic heart failure. Circulation 107 (2003) 1991-1997
10. Gavin A.D., and Struthers A.D. Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure. Heart 91 (2005) 749-753
11. Lee L., Horowitz J., and Frenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J 25 (2004) 634-641
12. Ciapponi A., Pizarro R., and Harrison J. Trimetazidine for stable angina. Cochrane Database Syst Rev 4 (2005) CD003614.
13. Chaitman B. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation 113 (2006) 2462-2472